Search Results - laura+blair

6 Results

Sort By:

Modulating Molecular Chaperone DnaJB6b as a Novel Method to Regulate Tau Seeding and Propagation

Advantages: Semi-high throughput screening accelerates drug discovery by quickly identifying candidates, reducing time to market, and gaining a competitive edge. Molecular Chaperone reduces tau aggregation, preserving cognitive function and improving patient quality. Employs a precision medicine approach targeting tauopathy mechanisms, potentially...

Published: 9/11/2024 | Inventor(s): Abigail Esquivel, Laura Blair

Keywords(s): Alzheimer's Disease, Neurodegenerative Diseases

Category(s): Technology Classifications > Medical > Neuroscience, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Therapeutics

Conditional FKBP51 Over-expression Transgenic Mouse

Advantages: Created a transgenic mice model that allows researchers to precisely control the expression of human FKBP51. Offers a tailored approach to studying psychiatric disorders, enabling the development of personalized treatments. Enhances the understanding of the molecular mechanisms underlying psychiatric disorders such as depression,...

Published: 11/13/2024 | Inventor(s): Chad Dickey(VA) (DECEASED - See Notes), Laura Blair, Bo Zhang

Keywords(s): Animal Models, Psychiatry / Mental Health

Category(s): Technology Classifications > Research Tools/Copyright > Animal Models, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Biomedical Engineering, Technology Classifications > Medical > Medical Diagnostics, Technology Classifications > Medical > Neuroscience, Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical > Therapeutics

Method of Treating Long-COVID Induced Neurologic Diseases

Advantages: Method of preventing AD onset following severe COVID RNA Nano-carrier system carrying dual (brain and CNS)-targeted dendriplexes to target the brain and CNS Summary: COVID-19 is primarily a respiratory disease; however, neurological symptoms are also reported in a subpopulation of infected COVID-19 individuals. Complementary...

Published: 4/26/2024 | Inventor(s): Subhra Mohapatra, Shyam Mohapatra, Paula Bickford, Laura Blair, Bala Chandran, Karthick Mayilsamy, Ryan Green

Keywords(s):

Category(s): Technology Classifications > Medical > Neuroscience

Neuronal suppression of FKBP51 expression by fatty acid derivatives to prevent mental disorders

Advantages: The study highlights FKBP51 as a promising target for the treatment of disorders such as major depression, PTSD, anxiety disorders, and Alzheimer's disease. The research recognizes the influence of single nucleotide polymorphisms (SNPs) in the FKBP5 gene on FKBP51 levels and susceptibility to certain disorders. The researchers...

Published: 9/3/2024 | Inventor(s): Charles Lockwood, Laura Blair, Ozlem Guzeloglu-Kayisli, Umit Kayisli

Keywords(s): Biotechnology, Medical Pharmaceuticals, Neurodegenerative Diseases, Therapeutics

Category(s): Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Neuroscience, Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical > Therapeutics

sHSP22 Improves Cognition and Learning Independently of Tau

Competitive Advantages Potential treatment for neurodegenerative diseases Hsp22 overexpression does not alter tau levels or tau phosphorylation status Hsp22 overexpression improved reversal spatial learning thus preserves learning and memory Summary Tau is a microtubule associated protein that has been linked to multiple neurodegenerative...

Published: 11/5/2024 | Inventor(s): Laura Blair, Paula Bickford

Keywords(s): Medical Therapeutics Gene Therapy, Neurodegenerative Diseases

Category(s): Technology Classifications > Medical > Neuroscience, Technology Classifications > Medical

Treating Pathological Tau Aggregates by Inhibiting the HSP90 Activator AHA1

Competitive Advantages Targets underlying pathology of Alzheimer’s disease and other tauopathies Cell studies show inhibition of Hsp 90 co-factor Aha1 reduces tau aggregation HSP90 and its co-factors provide novel drug target for future research Summary Pathogenic tau aggregation is one of the major hallmarks associated with...

Published: 2/13/2024 | Inventor(s): Chad Dickey(VA) (DECEASED - See Notes), Lindsey Shelton, Brian Blagg, John Koren, Laura Blair

Keywords(s):

Category(s): Technology Classifications > Medical, Technology Classifications > Medical > Neuroscience